Abstract
Background
To validate a new practical Sepsis Severity Score for patients with complicated intra-abdominal infections (cIAIs) including the clinical conditions at the admission (severe sepsis/septic shock), the origin of the cIAIs, the delay in source control, the setting of acquisition and any risk factors such as age and immunosuppression.
Methods
The WISS study (WSES cIAIs Score Study) is a multicenter observational study underwent in 132 medical institutions worldwide during a four-month study period (October 2014-February 2015). Four thousand five hundred thirty-three patients with a mean age of 51.2 years (range 18–99) were enrolled in the WISS study.
Results
Univariate analysis has shown that all factors that were previously included in the WSES Sepsis Severity Score were highly statistically significant between those who died and those who survived (p < 0.0001). The multivariate logistic regression model was highly significant (p < 0.0001, R2 = 0.54) and showed that all these factors were independent in predicting mortality of sepsis. Receiver Operator Curve has shown that the WSES Severity Sepsis Score had an excellent prediction for mortality. A score above 5.5 was the best predictor of mortality having a sensitivity of 89.2 %, a specificity of 83.5 % and a positive likelihood ratio of 5.4.
Conclusions
WSES Sepsis Severity Score for patients with complicated Intra-abdominal infections can be used on global level. It has shown high sensitivity, specificity, and likelihood ratio that may help us in making clinical decisions.
Keywords: Intra-abdominal, Infections, Sepsis, Septic shock
Background
Intra-abdominal infections (IAIs) include several different pathological conditions [1] and are usually classified into uncomplicated and complicated. In complicated IAIs (cIAIs), the infectious process extends beyond the organ, and causes either localized peritonitis or diffuse peritonitis. The treatment of patients with complicated intra-abdominal infections involves both source control and antibiotic therapy. Complicated IAIs are an important cause of morbidity and may be associated with poor prognosis. However the term “complicated intra-abdominal infections” describes a wide heterogeneity of patient populations, making it difficult to suggest a general treatment regimen and stressing the need of an individualized approach to decision making.
Early prognostic evaluation of complicated intra-abdominal infections is crucial to assess the severity and decide the aggressiveness of treatment. Many factors influencing the prognosis of patients with cIAIs have been described, including advanced age, poor nutrition, pre-existing diseases, immunosuppression, extended peritonitis, occurrence of septic shock, poor source control, organ failures, prolonged hospitalization before therapy, and infection with nosocomial pathogens [2–10].
Recently the World Society of Emergency Surgery (WSES) designed a global prospective observational study (CIAOW Study) [11, 12]. All the risk factors for occurrence of death during hospitalization were evaluated and then discussed with an international panel of experts. The most significant variables, adjusted to clinical criteria, were used to create a severity score for patients with cIAIs including the clinical conditions at admission (severe sepsis/septic shock), the origin of the cIAIs, the delay in source control, the setting of acquisition and any risk factors such as age and immunosuppression (Appendix).
There may be different causes of sepsis, health care standards, and differences in underlying health status, economical differences that make prediction of sepsis on global level difficult. The WSES addressed this issue in the present study which aims to validate a previous score on a global level.
Methods
Ethical statement
The study met the standards outlined in the Declaration of Helsinki and Good Epidemiological Practices. This study did not change or modify the laboratory or clinical practices of each centre and differences of practices were kept as they are. The data collection was anonymous and identifiable patient information was not submitted.
Individual researchers were responsible for complying with local ethical standards and hospital registration of the study.
Study population
This multicenter observational study was run in 132 medical institutions from 54 countries worldwide during a four-month period (October 2014-February 2015). Inclusion criteria were patients older than 18 years with complicated intra-abdominal sepsis (cIAIs) who had surgical management or interventional radiological drainage. cIAIs was defined as an infectious process that proceeded beyond the organ, and caused either localized peritonitis/abscess or diffuse peritonitis [13]. Patients who were younger than 18 years, or those who had pancreatitis, or primary peritonitis were excluded from the study. Severe sepsis was defined as sepsis-induced tissue hypoperfusion or organ dysfunction (any of the following thought to be due to the infection): hypotension (<90/60 or MAP < 65), lactate above upper limits laboratory normal, Urine output < 0.5 mL/kg/h for more than 2 h despite adequate fluid resuscitation, Creatinine > 2.0 mg/dL (176.8 μmol/L), Bilirubin > 2 mg/dL (34.2 μmol/L), Platelet count < 100,000 μL, Coagulopathy (international normalized ratio > 1.5), Acute lung injury with Pao2/Fio2 < 250 in the absence of pneumonia as infection source. Septic shock was defined as severe sepsis associated with refractory hypotension (BP < 90/60) despite adequate fluid resuscitation [14].
WSES Sepsis Severity Score for patients with complicated Intra-abdominal infections is shown in Appendix.
Data monitoring and collection
The study was monitored by the coordination center, which investigated and verified missing or unclear data submitted to the central database. This study was performed under the direct supervision of the Board of Directors of WSES. In each centre, the coordinator collected and compiled data in an online case report system. Data were entered directly through a web-based computerized database. Data were entered either by a drop menu for categorical data like the source of infection or numbers for continuous variables such as age. Data collected included demographic data of the patient and disease characteristics, demographical data, type of infection (community- or healthcare-acquired), severity criteria and origin of infection and surgical procedures performed.
Statistical analysis
Sepsis status was coded as ordinal data for testing the logistic regression (not for scoring) as follows: no sepsis = 0, sepsis = 2, severe sepsis = 3, septic shock = 4). The source of sepsis was analysed as categorical data in the logistic regression, and the age as continuous data, while healthcare associated infection, delay in management, and immunosuppression as binomial data. The variables used in this scoring system in the patients who survived and those who died were compared using univariate analysis. This included Fisher’s exact test or Pearson Chi-Square as appropriate for categorical data and Mann–Whitney U-test for continuous or ordinal data. Significant factors were then entered into a direct logistic regression model. A p value of ≤ 0.05 was considered significant. Data were analyzed with PASW Statistics 21, SPSS Inc, USA.
Results
Four thousand six hundred fifty-two cases were collected in the online case report system. One hundred twenty-nine cases did not meet the inclusion criteria. Four thousand five hundred thirty-three patients with a mean age of 51.2 years (range 18–99) were enrolled in the WISS study. One thousand nine hundred thirty-five patients (42.7 %) were women and 2598 (57.3 %) were men.
Among these patients, 3966 (87.5 %) were affected by community-acquired IAIs while the remaining 567 (12.5 %) suffered from healthcare-associated infections. One thousand six hundred twenty-seven patients (35.9 %) were affected by generalized peritonitis while 2906 (64.1 %) suffered from localized peritonitis or abscesses. Seven hundred ninety-one patients (17.4 %) were admitted in critical condition (severe sepsis/septic shock). The various sources of infection are outlined in Table 1. The most frequent source of infection was acute appendicitis; 1553 cases (34.2 %) involved complicated appendicitis.
Table 1.
Source of infection | Number (%) |
---|---|
Appendicitis | 1553 (34.2 %) |
Cholecystitis | 837 (18.5 %) |
Post-operative | 387 (8.5 %) |
Colonic non diverticular perforation | 269 (5.9 %) |
Gastro-duodenal perforations | 498 (11 %) |
Diverticulitis | 234 (5.2 %) |
Small bowel perforation | 243 (5.4 %) |
Others | 348 (7.7 %) |
PID | 50 (1.1 %) |
Post traumatic perforation | 114 (2.5 %) |
Missing | |
Total | 4553 (100 %) |
PID pelvic inflammatory disease
The overall mortality rate was 9.2 % (416/4533).
Table 2 shows the univariate analysis comparing patients with complicated intra-abdominal infection who survived and those who died. The analysis shows that all factors included in the Sepsis Severity Score were highly significantly different between those who died and those who survived (p < 0.0001 in all variables). Accordingly all factors were entered into a direct logistic regression model (Table 3). The direct logistic regression model was highly significant (p < 0.0001, R2 = 0.54) and showed that all factors included in the Sepsis Severity Score were significant independent predictors of mortality. Accordingly the ability of the score to predict mortality was tested by a direct logistic regression which is shown in Table 4. Again, this model using only the sepsis severity score was highly significant (p < 0.0001, R2 = 0.5). The odds of death increased by 0.78 by an increase on one score which is remarkable.
Table 2.
Variable | Survided (%) n = 4117 | Died (%) n = 416 | p value |
---|---|---|---|
Sepsis status | <0.0001 | ||
No sepsis | 1914 (46.5 %) | 23 (5.5 %) | |
Sepsis | 1725 (41.9 %) | 80 (19.2 %) | |
Severe sepsis | 404 (9.8 %) | 157 (37.7 %) | |
Septic shock | 74 (1.8 %) | 156 (37.5 %) | |
Healthcare associated infection | 433 (10.5 %) | 134 (32.2 %) | <0.0001 |
Source of infection | <0.0001 | ||
Appendicitis | 1536 (37.3 %) | 17 (4.1 %) | |
Cholecystitis | 809 (19.7 %) | 28 (6.7 %) | |
Colonic non diverticular perforation | 204 (5 %) | 65 (15.6 %) | |
Diverticulitis | 203 (4.9 %) | 31 (7.5 %) | |
Gastro-duodenal perforation | 431 (10.5 %) | 67 (16.2 %) | |
PID | 50 (1.2 %) | 0 (0) | |
Postoperative | 415 (10.1 %) | 86 (20.7 %) | |
Small bowel perforation | 174 (4.2 %) | 69 (16.6 %) | |
Post-traumatic | 104 (2.5 %) | 10 (2.4 %) | |
Others | 259 (6.3 %) | 53 (12.7 %) | |
Delay in source control | 2015 (48.9 %) | 341 (82 %) | <0.0001 |
Median age years (range) | 48 (18–97) | 79 (18–99) | <0.0001 |
Immunosuppresion | 292 (7.1) | 120 (28.8 %) | <0.0001 |
Sepsis severity score | 3 (0–17) | 10 (0–17) | <0.0001 |
Data presented as median range or number percentage as appropriate
PID pelvic inflammatory disease
p value = Fisher’s exact test, Pearson Chi-Square, or Mann Whitney U test as appropriate
Table 3.
Score variable | B | S.E. | Wald test | P value | OR | OR 95 % C.I. | |
---|---|---|---|---|---|---|---|
Lower | Upper | ||||||
Sepsis status | 1.57 | 0.08 | 365.59 | <0.0001 | 4.81 | 4.09 | 5.65 |
Setting of infection acquisition | 0.6 | 0.18 | 10.49 | 0.001 | 1.81 | 1.27 | 2.6 |
Source of infectiona | 59.38 | <0.0001 | |||||
Colonic non-diverticulical perforation | −0.26 | 0.27 | 0.97 | 0.33 | 0.77 | 0.46 | 1.3 |
Diverticulitis diffuse peritonitis | −0.26 | 0.34 | 0.51 | 0.48 | 0.78 | 0.40 | 1.54 |
Postoperative diffuse peritonitis | −0.005 | 0.29 | 0 | 0.99 | 1.00 | 0.56 | 1.76 |
Remaining sources | −1.2 | 0.21 | 32.47 | <0.0001 | 0.30 | 0.20 | 0.46 |
Delay in management | 1.47 | 0.17 | 78.53 | <0.0001 | 4.33 | 3.13 | 5.99 |
Age | 0.04 | 0.004 | 103.58 | <0.0001 | 1.04 | 1.04 | 1.05 |
Immunosuppression | 1.24 | 0.17 | 55.79 | <0.0001 | 3.46 | 2.5 | 4.79 |
Constant | −7.52 | 0.41 | 342.24 | <0.0001 | 0.001 |
OR odds ratio
aCompared with small bowel perforation
Table 4.
Variable | B | S.E. | Wald | P value | OR | OR 95 % C.I. | |
---|---|---|---|---|---|---|---|
Lower | Upper | ||||||
WSESSCORE | 0.58 | 0.02 | 639.59 | <0.0001 | 1.784 | 1.706 | 1.866 |
Constant | −5.79 | 0.19 | 958.74 | <0.0001 | .003 |
OR odds ratio
Figure 1 shows that WSES Sepsis Severity Score had a very good ability of distinguishing those who survived from those who died. The overall mortality rate was 9.2 % (416/4533). This was 0.63 % for those who had a score of 0–3, 6.3 % for those who had a score of 4–6, and 41.7 % for those who had a score of ≥ 7. The receiver operating characteristic curve showed that the best cutoff point for predicting mortality was a Sepsis Severity Score. 5.5 was the best predictor of mortality having a sensitivity of 89.2 %, a specificity of 83.5 % and a positive likelihood ratio of 5.4 (Fig. 2).
Discussion
Complicated intra-abdominal infections remain an important source of patient morbidity and may be frequently associated with poor clinical prognosis. Treatment of patients with cIAIs, has been usually described to achieve satisfactory results if adequate management is established [15]. However, results from published clinical trials may not be representative of the true morbidity and mortality rates of such severe infections. First of all, patients who have perforated appendicitis are usually over-represented in clinical trials. Furthermore patients with intra-abdominal infection enrolled in clinical trials have often an increased likelihood of cure and survival. In fact the trial eligibility criteria usually restrict the inclusion of patients with co-morbid diseases that would increase the death rate of patients with intra-abdominal infections [16]. In the WISS study we enrolled all the patients older than 18 years old with complicated intra-abdominal infections in the study-period and the overall mortality rate was 9.2 % (416/4533). Stratification of the patient’s risk is essential in order to optimize the treatment plan. Patients with intra-abdominal infections are generally classified into low risk and high risk. “High risk” is generally intended to describe patients with a high risk for treatment failure and mortality. In high risk patients the increased mortality associated with inappropriate management cannot be reversed by subsequent modifications. Therefore early prognostic evaluation of complicated intra-abdominal infections is important to assess the severity and decide the aggressiveness of treatment.
Scoring systems can be roughly divided into two groups: disease-independent scores for evaluation of serious patients requiring care in the intensive care unit (ICU) such as APACHE II and Simplified Acute Physiology Score (SAPS II) and peritonitis-specific scores such as Mannheim Peritonitis Index (MPI) [17].
Although considered a good marker, APACHE II value in peritonitis has been questioned because of the difficulty of the APACHE II to evaluate interventions despite the fact that interventions might significantly alter many of the physiological variables. Moreover it requires appropriate software to be calculated [18].
The MPI is specific for peritonitis and easy to calculate. MPI was designed by Wacha and Linder in 1983 [19]. It was based on a retrospective analysis of data from 1253 patients with peritonitis. Among 20 possible risk factors, only 8 proved to be of prognostic relevance and were entered into the Mannheim Peritonitis Index, classified according to their predictive power. After 30 years, identifying a new clinical score to assess the severity the cIAIS would be clinically relevant in order to modulate the aggressiveness of treatment according the type of infection and the clinical characteristics of the patients.
WSES Sepsis Severity Score is a new practical clinical severity score for patients with complicated intra-abdominal infections. It is specific for cIAIs and easy to calculate, even during surgery. It may be relevant in order to modulate the aggressiveness of treatment particularly in higher risk patients.
The score is illustrated in Appendix. The statistical analysis shows that the sepsis severity score has a very good ability of distinguishing those who survived from those who died. The overall mortality was 0.63 % for those who had a score of 0–3, 6.3 % for those who had a score of 4–6, 41.7 % for those who had a score of ≥ 7. In patients who had a score of ≥ 9 the mortality rate was 55.5 %, those who had a score of ≥ 11 the mortality rate was 68.2 % and those who had a score ≥ 13 the mortality rate was 80.9 %.
Conclusions
Given the sweeping geographical distribution of the participating medical centers, WSES Sepsis Severity Score for patients with complicated Intra-abdominal infections can be used on global level. It has shown high sensitivity, specificity, and likelihood ratio that may help us in making clinical decisions.
Appendix
Table 5.
Clinical condition at the admission | |
• Severe sepsis (acute organ dysfunction) at the admission | 3 score |
• Septic shock (acute circulatory failure characterized by persistent arterial hypotension. It always requires vasopressor agents) at the admission | 5 score |
Setting of acquisition | |
• Healthcare associated infection | 2 score |
Origin of the IAIs | |
• Colonic non-diverticular perforation peritonitis | 2 score |
• Small bowel perforation peritonitis | 3 score |
• Diverticular diffuse peritonitis | 2 score |
• Post-operative diffuse peritonitis | 2 score |
Delay in source control | |
• Delayed initial intervention [Preoperative duration of peritonitis (localized or diffuse) > 24 h)] | 3 score |
Risk factors | |
• Age>70 | 2 score |
• Immunosuppression (chronic glucocorticoids, immunosuppresant agents, chemotherapy, lymphatic diseases, virus) | 3 score |
Footnotes
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MS designed the study and wrote the manuscript. FMA-Z performed statistical analysis. All authors participated in the study. All authors read and approved the final manuscript.
Contributor Information
Massimo Sartelli, Email: massimosartelli@gmail.com.
Fikri M. Abu-Zidan, Email: fabuzidan@uaeu.ac.ae
Fausto Catena, Email: faustocatena@gmail.com.
Ewen A. Griffiths, Email: ewenagriffiths@gmail.com
Salomone Di Saverio, Email: salo75@inwind.it.
Raul Coimbra, Email: rcoimbra@ucsd.edu.
Carlos A. Ordoñez, Email: ordonezcarlosa@gmail.com
Ari Leppaniemi, Email: ari.leppaniemi@hus.fi.
Gustavo P. Fraga, Email: fragagp2008@gmail.com
Federico Coccolini, Email: federico.coccolini@gmail.com.
Ferdinando Agresta, Email: fagresta@libero.it.
Asrhaf Abbas, Email: ashrafabbaas@hotmail.com.
Saleh Abdel Kader, Email: skader@alain-hospital.ae.
John Agboola, Email: owoade14@gmail.com.
Adamu Amhed, Email: mrahmed1010@yahoo.com.
Adesina Ajibade, Email: ajifada2@gmail.com.
Seckin Akkucuk, Email: sakkucuk@mku.edu.tr.
Bandar Alharthi, Email: Bnalharthi@kfmc.med.sa.
Dimitrios Anyfantakis, Email: danyfantakis@med.uoc.gr.
Goran Augustin, Email: augustin.goran@gmail.com.
Gianluca Baiocchi, Email: gianluca.baiocchi@unibs.it.
Miklosh Bala, Email: rbalam@hadassah.org.il.
Oussama Baraket, Email: oubaraket@gmail.com.
Savas Bayrak, Email: savasbayrak74@gmail.com.
Giovanni Bellanova, Email: giovanni.bellanova@asl.taranto.it.
Marcelo A. Beltràn, Email: beltran_01@yahoo.com
Roberto Bini, Email: re.bini@libero.it.
Matthew Boal, Email: Matthew.Boal@uhb.nhs.uk.
Andrey V. Borodach, Email: aborodach@gmail.com
Konstantinos Bouliaris, Email: kwstisbool@yahoo.com.
Frederic Branger, Email: frederic.branger@chu-angers.fr.
Daniele Brunelli, Email: danielebrunelli2009@libero.it.
Marco Catani, Email: marco.catani@uniroma1.it.
Asri Che Jusoh, Email: asricj@yahoo.com.
Alain Chichom-Mefire, Email: alainchichom@yahoo.com.
Gianfranco Cocorullo, Email: gianfranco.cocorullo@unipa.it.
Elif Colak, Email: elifmangancolak@hotmail.com.
David Costa, Email: dcostacir@gmail.com.
Silvia Costa, Email: sisse.costa@gmail.com.
Yunfeng Cui, Email: yunfengcuidoctor@aliyun.com.
Geanina Loredana Curca, Email: geaninacurca@gmail.com.
Terry Curry, Email: tcurry@ucsd.edu.
Koray Das, Email: koraydas@yahoo.com.
Samir Delibegovic, Email: delibegovic.samir@gmail.com.
Zaza Demetrashvili, Email: zdemetr@yahoo.com.
Isidoro Di Carlo, Email: idicarlo@unict.it.
Nadezda Drozdova, Email: nadja86lv@gmail.com.
Tamer El Zalabany, Email: dtzalabany@hotmail.com.
Mushira Abdulaziz Enani, Email: menani@kfmc.med.sa.
Mario Faro, Email: mariofaro31@hotmail.com.
Mahir Gachabayov, Email: gachabayovmahir@gmail.com.
Teresa Giménez Maurel, Email: teresagm87@gmail.com.
Georgios Gkiokas, Email: georgiokas@yahoo.com.
Carlos Augusto Gomes, Email: caxiaogomes@gmail.com.
Ricardo Alessandro Teixeira Gonsaga, Email: novo02@uol.com.br.
Gianluca Guercioni, Email: gianmed@libero.it.
Ali Guner, Email: draliguner@yahoo.com.
Sanjay Gupta, Email: SANDIV99@YAHOO.CO.UK.
Sandra Gutierrez, Email: sandragutierrezmd@gmail.com.
Martin Hutan, Email: matohuto@yahoo.com.
Orestis Ioannidis, Email: onakos@hotmail.com.
Arda Isik, Email: kararda@yahoo.com.
Yoshimitsu Izawa, Email: damagecontrolresuscitation@gmail.com.
Sumita A. Jain, Email: sumitajain@gmail.com
Mantas Jokubauskas, Email: mantas910317@gmail.com.
Aleksandar Karamarkovic, Email: alekara@sbb.rs.
Saila Kauhanen, Email: saila.kauhanen@utu.fi.
Robin Kaushik, Email: robinkaushik@yahoo.com.
Jakub Kenig, Email: jkenig@cm-uj.krakow.pl.
Vladimir Khokha, Email: docvladimir@yandex.ru.
Jae Il Kim, Email: erythrokim@paik.ac.kr.
Victor Kong, Email: victorywkong@yahoo.com.
Renol Koshy, Email: renolkoshy@gmail.com.
Avidyl Krasniqi, Email: avdyl.krasniqi@yahoo.com.
Ashok Kshirsagar, Email: kshirsagarashok007@gmail.com.
Zygimantas Kuliesius, Email: kzygimantas@yahoo.com.
Konstantinos Lasithiotakis, Email: kwstaslasith@yahoo.gr.
Pedro Leão, Email: pedroleao@ecsaude.uminho.pt.
Jae Gil Lee, Email: jakii@yuhs.ac.
Miguel Leon, Email: miguel.leon.arellano@gmail.com.
Aintzane Lizarazu Pérez, Email: aintzanelizarazu@hotmail.com.
Varut Lohsiriwat, Email: bolloon@hotmail.com.
Eudaldo López-Tomassetti Fernandez, Email: dretomassetti@gmail.com.
Eftychios Lostoridis, Email: e.lostoridis@gmail.com.
Raghuveer Mn, Email: dr.raghuveermn@gmail.com.
Piotr Major, Email: majorpiotr@gmail.com.
Athanasios Marinis, Email: drmarinis@gmail.com.
Daniele Marrelli, Email: daniele.marrelli@unisi.it.
Aleix Martinez-Perez, Email: aleix.martinez.perez@gmail.com.
Sanjay Marwah, Email: drsanjay.marwah@gmail.com.
Michael McFarlane, Email: michaelm500@yahoo.com.
Renato Bessa Melo, Email: rbmelo@med.up.pt.
Cristian Mesina, Email: mesina.cristian@doctor.com.
Nick Michalopoulos, Email: nickos.michalopoulos@gmail.com.
Radu Moldovanu, Email: rmoldovanu@gmail.com.
Ouadii Mouaqit, Email: mouaqit.ouadii@gmail.com.
Akutu Munyika, Email: mbwale@yahoo.com.
Ionut Negoi, Email: negoiionut@gmail.com.
Ioannis Nikolopoulos, Email: inikolopoulos@gmail.com.
Gabriela Elisa Nita, Email: gnita@hpg23.it.
Iyiade Olaoye, Email: tunde_olaoye_dr@yahoo.com.
Abdelkarim Omari, Email: akomari@just.edu.jo.
Paola Rodríguez Ossa, Email: docossa@hotmail.com.
Zeynep Ozkan, Email: drzeynepozkan@yahoo.com.
Ramakrishnapillai Padmakumar, Email: drrpadmakumar@gmail.com.
Francesco Pata, Email: francesco.pata@gmail.com.
Gerson Alves Pereira Junior, Email: gersonapj@fmrp.usp.br.
Jorge Pereira, Email: docjota@netcabo.pt.
Tadeja Pintar, Email: tadeja.pintar@kclj.si.
Konstantinos Pouggouras, Email: pougouras@gmail.com.
Vinod Prabhu, Email: cghert@yahoo.co.in.
Stefano Rausei, Email: stefano.rause@ospedale.varese.it.
Miran Rems, Email: Miran.rems@sb-je.si.
Daniel Rios-Cruz, Email: jobzon@hotmail.com.
Boris Sakakushev, Email: bsakakushev@gmail.com.
Maria Luisa Sánchez de Molina, Email: mluisa.sanchezdemolina@hotmail.com.
Charampolos Seretis, Email: babismed@gmail.com.
Vishal Shelat, Email: vgshelat@rediffmail.com.
Romeo Lages Simões, Email: romeolages@hotmail.com.
Giovanni Sinibaldi, Email: giovanni.sinibaldi@gmail.com.
Matej Skrovina, Email: matej.skrovina@nnj.agel.cz.
Dmitry Smirnov, Email: surgeon.smirnov@yahoo.com.
Charalampos Spyropoulos, Email: charisspyropoulos@gmail.com.
Jaan Tepp, Email: jaan.tepp@regionaalhaigla.ee.
Tugan Tezcaner, Email: tugant@baskent-ank.edu.tr.
Matti Tolonen, Email: infonew@wses.org.uk.
Myftar Torba, Email: myftartorba@yahoo.com.
Jan Ulrych, Email: Jan.Ulrych@vfn.cz.
Mustafa Yener Uzunoglu, Email: drmyuzunoglu@gmail.com.
David van Dellen, Email: david.vandellen@cmft.nhs.uk.
Gabrielle H. van Ramshorst, Email: g.vanramshorst@vumc.nl
Giorgio Vasquez, Email: giorgio.vasquez@unife.it.
Aurélien Venara, Email: auvenara@yahoo.fr.
Andras Vereczkei, Email: vereczkei.andras@pte.hu.
Nereo Vettoretto, Email: nereovet@gmail.com.
Nutu Vlad, Email: nutu.vlad@gmail.com.
Sanjay Kumar Yadav, Email: sky1508@gmail.com.
Tonguç Utku Yilmaz, Email: utku.yilmaz@kocaeli.edu.tr.
Kuo-Ching Yuan, Email: traumayuan@gmail.com.
Sanoop Koshy Zachariah, Email: skzach@yahoo.com.
Maurice Zida, Email: zimaur@yahoo.fr.
Justas Zilinskas, Email: justas.zilinskas@gmail.com.
Luca Ansaloni, Email: lansaloni@hpg23.it.
References
- 1.Sartelli M, Viale P, Catena F, Ansaloni L, Moore E, Malangoni M, et al. 2013 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg. 2013;8(1):3. doi: 10.1186/1749-7922-8-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Mulari K, Leppäniemi A. Severe secondary peritonitis following gastrointestinal tract perforation. Scand J Surg. 2004;93(3):204–8. doi: 10.1177/145749690409300306. [DOI] [PubMed] [Google Scholar]
- 3.Horiuchi A, Watanabe Y, Doi T, Sato K, Yukumi S, Yoshida M, et al. Evaluation of prognostic factors and scoring system in colonic perforation. World J Gastroenterol. 2007;13(23):3228–31. doi: 10.3748/wjg.v13.i23.3228. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Evans HL, Raymond DP, Pelletier SJ, Crabtree TD, Pruett TL, Sawyer KG. Tertiary peritonitis (recurrent diffuse or localized disease) is not an independent predictor of mortality in surgical patients with intra-abdominal infection. Surg Infect. 2001;2:255–65. doi: 10.1089/10962960152813296. [DOI] [PubMed] [Google Scholar]
- 5.McLauchlan GJ, Anderson ID, Grant IS, Fearon KCH. Outcome of patients with abdominal sepsis treated in an intensive care unit. Br J Surg. 1995;82:524–9. doi: 10.1002/bjs.1800820429. [DOI] [PubMed] [Google Scholar]
- 6.Koperna T, Schulz F. Prognosis and treatment of peritonitis: Do we need new scoring systems? Arch Surg. 1996;131:180–6. doi: 10.1001/archsurg.1996.01430140070019. [DOI] [PubMed] [Google Scholar]
- 7.Pacelli F, Doglietto GB, Alfieri S, Piccioni E, Sgadari A, Gui D, et al. Prognosis in intra-abdominal infections. Multivariate analysis on 604 patients. Arch Surg. 1996;131:641–5. doi: 10.1001/archsurg.1996.01430180067014. [DOI] [PubMed] [Google Scholar]
- 8.Ohmann C, Yang Q, Hau T, Wacha H, the Peritonitis Study Group of the Surgical Infection Society Europe Prognostic modelling in peritonitis. Eur J Surg. 1997;163:53–60. [PubMed] [Google Scholar]
- 9.Montravers P, Gauzit R, Muller C, Marmuse JP, Fichelle A, Desmonts JM. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intra-abdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis. 1996;23:486–94. doi: 10.1093/clinids/23.3.486. [DOI] [PubMed] [Google Scholar]
- 10.Prabhu V, Shivani A. An overview of history, pathogenesis and treatment of perforated peptic ulcer disease with evaluation of prognostic scoring in adults. Ann Med Health Sci Res. 2014;4(1):22–9. doi: 10.4103/2141-9248.126604. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Sartelli M, Catena F, Ansaloni L, Leppaniemi A, Taviloglu K, van Goor H, et al. Complicated intra-abdominal infections in Europe: a comprehensive review of the CIAO study. World J Emerg Surg. 2012;7(1):36. doi: 10.1186/1749-7922-7-36. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Sartelli M, Catena F, Ansaloni L, Coccolini F, Corbella D, Moore EE, et al. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study. World J Emerg Surg. 2014;9:37. doi: 10.1186/1749-7922-9-37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Sartelli M. A focus on intra-abdominal infections. World J Emerg Surg. 2010;5:9. doi: 10.1186/1749-7922-5-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165–228. doi: 10.1007/s00134-012-2769-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Mazuski JE, Solomkin JS. Intra-abdominal infections. Surg Clin North Am. 2009;89(2):421–37. doi: 10.1016/j.suc.2008.12.001. [DOI] [PubMed] [Google Scholar]
- 16.Merlino JI, Malangoni MA, Smith CM, Lange RL. Prospective randomized trials affect the outcomes of intraabdominal infection. Ann Surg. 2001;233(6):859–66. doi: 10.1097/00000658-200106000-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Komatsu S, Shimomatsuya T, Nakajima M, Amaya H, Kobuchi T, Shiraishi S, et al. Prognostic factors and scoring system for survival in colonic perforation. Hepatogastroenterology. 2005;52:761–64. [PubMed] [Google Scholar]
- 18.Koperna T, Semmler D, Marian F. Risk stratification in emergency surgical patients: is the APACHE II score a reliable marker of physiological impairment? Arch Surg. 2001;136(1):55–9. doi: 10.1001/archsurg.136.1.55. [DOI] [PubMed] [Google Scholar]
- 19.Wacha H, Linder MM, Feldman U, Wesch G, Gundlach E, Steifensand RA. Mannheim peritonitis index – prediction of risk of death from peritonitis: construction of a statistical and validation of an empirically based index. Theor Surg. 1987;1:169–77. [Google Scholar]